My plan is to execute a bifurcated strategy that leverages high-conviction, catalyst-driven speculation to systematically fund and accumulate a fortress portfolio of durable, quality compounders.
https://www.youtube.com/@TheInvertedInvestor
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
By: The Forensic Analyst | Simply Wall St In the chaotic world of equity markets, price and value often diverge. But rarely do they divorce as violently as we are currently seeing with Ubisoft Entertainment SA (UBI.PA).Read more
QDay is coming - 01 Quantum hold the key
01 Quantum Inc. (formerly 01 Communique) has spent nearly a decade in quiet R&D, positioning itself as a first-to-market provider of software designed to protect the digital world from the existential threat of quantum computers.Read more
Buy, Hold and Profit. Solid Value
Buy, Hold , Profit. We are not in the business of predicting when, or even if, a stock will rise.Read more
The "Molecular Pencil": Why Beam's Technology is Built to Win
The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more
alphabet: Long Term Strategic Powerhouse
Alphabet, the parent company of Google, has consistently demonstrated its prowess in innovation and strategic foresight. While the recent quarterly results have showcased impressive financial performance, it's the company's relentless pursuit of long-term value creation that truly sets it apart.Read more
Berkshire Hathaway: A Fortress of Financial Strength
Berkshire Hathaway: A Fortress of Financial Strength Berkshire Hathaway, the investment conglomerate led by the legendary Warren Buffett, has long been admired for its disciplined investment strategy, long-term focus, and unwavering commitment to shareholder value. As the company prepares for the eventual transition of leadership to Greg Abel, it's essential to examine its financial strength and prospects for continued success.Read more
Is IonQ (IONQ) on Course to Become the "Nvidia of Quantum"?
Following a landmark earnings report, a new "800-pound gorilla" has been uncaged. We analyze the three-part moat that has de-risked IonQ’s "100-Bagger" thesis.Read more
Kodiak AI - a potential 100 bagger opportunity?
Kodiak AI - a potential 100 bagger opportunity? Investment Analysis: Kodiak AI, Inc.Read more
Schrödinger will Transform Drug Discovery with 24% Growth
Schrödinger stands at the confluence of biotechnology, materials science, and enterprise software, pioneering a transformation in the field of molecular discovery. The company has moved beyond the traditional silos of either a software provider or a drug developer to create a hybrid enterprise.Read more